PRA Health Sciences (PRAH) Stock Price, News & Analysis

Company Overview

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Key Stats

• Today's Range: $165.21 to $165.21
• 50-Day Range: $165.21 to $174.52
• 52-Week Range: $93.00 to $175.95
• Volume: 57 shs
• Average Volume: 837,472 shs
• Market Capitalization: $10.70 billion
• P/E Ratio: 50.52
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRAH Stock Analysis - Frequently Asked Questions

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences, Inc. (NASDAQ:PRAH) issued its quarterly earnings data on Wednesday, April, 28th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.03. PRA Health Sciences's revenue for the quarter was up 19.1% on a year-over-year basis.

When did PRA Health Sciences IPO?

PRA Health Sciences (PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PRA Health Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Visa (V) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 4/28/2021
• Today: 7/14/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial Physical Research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PRAH
• CIK: 1613859
• Web: www.prahs.com
• Phone: (919) 786-8200
• Fax: N/A
• Employees: 18,100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $3.90
• Trailing P/E Ratio: 50.52
• Forward P/E Ratio: 31.29
• P/E Growth: N/A
• Net Income: $197.04 million
• Net Margins: 6.40%
• Pretax Margin: N/A
• Return on Equity: 20.49%
• Return on Assets: 7.07%

Debt

• Debt-to-Equity Ratio: 0.74
• Current Ratio: 1.21
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $3.18 billion
• Price / Sales: 3.36
• Cash Flow: $6.09 per share
• Price / Cash Flow: 27.11
• Book Value: $23.06 per share
• Price / Book: 7.16

Miscellaneous

• Outstanding Shares: 64,795,000
• Free Float: N/A
• Market Cap: $10.70 billion
• Optionable: Optionable
• Beta: 1.31